SCHEMBL6632216

SCHEMBL6632216

c1ccc(CN2CCCCNCC2)cc1

nearest known ligand 0.82

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.82
CXCR4 P61073 12/20 0.69
MEN1 O00255 2/20 0.69
KMT2A Q03164 2/20 0.69
HRH3 Q9Y5N1 2/20 0.69
CHRM2 P08172 1/20 0.69
CHRM1 P11229 1/20 0.69
ADRA2C P18825 1/20 0.69
CCR2 P41597 1/20 0.69
CXCL12 P48061 1/20 0.69
BLM P54132 1/20 0.69
TDP1 Q9NUW8 1/20 0.69
ALDH1A1 P00352 1/20 0.58
CYP2C9 P11712 1/20 0.58
TSHR P16473 1/20 0.58
CYP2C19 P33261 1/20 0.58
HIF1A Q16665 1/20 0.58
CYP2D6 P10635 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27300143 0.97 SIGMAR1 (0.77) SIGMAR1CXCR4MEN1KMT2AHRH3
Pyrrolidine SCHEMBL15516038 0.95 SIGMAR1 (0.72) SIGMAR1CXCR4MEN1KMT2AHRH3
SCHEMBL10316935 0.95 SIGMAR1 (0.85) SIGMAR1CXCR4MEN1KMT2AHRH3
SCHEMBL255099 0.95 SIGMAR1 (0.85) SIGMAR1CXCR4MEN1KMT2AHRH3
Hydrochloric Acid SCHEMBL7422770 0.93 SIGMAR1 (0.82) SIGMAR1CXCR4MEN1KMT2AHRH3
SCHEMBL31616422 0.93 SIGMAR1 (0.82) SIGMAR1CXCR4MEN1KMT2AHRH3
SCHEMBL3994310 0.91 CXCR4 (0.83) SIGMAR1CXCR4MEN1KMT2AHRH3
SCHEMBL15043649 0.91 SIGMAR1 (0.85) SIGMAR1CXCR4MEN1KMT2AHRH3
SCHEMBL3779720 0.91 CXCR4 (0.78) SIGMAR1CXCR4MEN1KMT2AHRH3
SCHEMBL6138636 0.91 SIGMAR1 (1.00) SIGMAR1CXCR4MEN1KMT2AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406900-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2004-04-14 EP claimed
WO-2003004493-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2003-01-16 WO claimed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
EP-1406900-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2004-04-14 EP disclosed
WO-2003004493-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 SIGMAR1 4230/4885CXCR4 3311/4885MEN1 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.